Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current drug metabolism

• Publication date

  2010-09-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/138920010794233495PMID 20942780PMCID PMC3028383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.

  2010cited by this paper
• beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO).

  2010cited by this paper
• Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

  2010cited by this paper
• Effects of herbal products on the metabolism and transport of anticancer agents

  2010cited by this paper
• Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia.

  2010cited by this paper
• How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments.

  2010cited by this paper
• Drug interactions

  2009cited by this paper
• Role of microRNAs in the regulation of drug metabolism and disposition

  2009cited by this paper
• Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.

  2009cited by this paper
• Implementation of CYP2D6 genotyping in psychiatry

  2009cited by this paper
• 5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition.

  2009cited by this paper
• Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines

  2009cited by this paper
• Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

  2009cited by this paper
• Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials

  2009cited by this paper
• Sudden death associated with intravenous injection of toad extract.

  2009cited by this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cited by this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cited by this paper
• Pharmacological characterization of harmaline-induced tremor activity in mice.

  2009cited by this paper
• Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.

  2009cited by this paper
• Drug-induced serotonin syndrome: a review

  2008cited by this paper
• The behavioral pharmacology of hallucinogens.

  2008cited by this paper
• Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions

  2008cited by this paper
• Identification of N,N-dimethyltryptamine and beta-carbolines in psychotropic ayahuasca beverage.

  2008cited by this paper
• Applications and limitations of genetically modified mouse models in drug discovery and development.

  2008cited by this paper
• Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration.

  2008cited by this paper
• Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors

  2008cited by this paper
• In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes.

  2007cited by this paper
• The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.

  2007cited by this paper
• A pharmacological analysis of mice with a targeted disruption of the serotonin transporter

  2007cited by this paper
• Quantitative measurement of postural sway in mouse models of human neurodegenerative disease.

  2007cited by this paper
• CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.

  2007cited by this paper
• A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action.

  2006cited by this paper
• The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats

  2006cited by this paper
• Cytochrome P450 and xenobiotic receptor humanized mice.

  2006cited by this paper
• Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.

  2006cited by this paper
• A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy.

  2006cited by this paper
• Effects of beta-carboline alkaloids on the object recognition task in mice.

  2006cited by this paper
• Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.

  2006cited by this paper
• Effects of harmaline on anxiety-related behavior in mice.

  2005cited by this paper
• Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats

  2005cited by this paper
• Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: behavioural and electrophysiological studies.

  2005cited by this paper
• A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation.

  2005cited by this paper
• The serotonin syndrome.

  2005cited by this paper
• Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test.

  2004cited by this paper
• Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine

  2004cited by this paper
• Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.

  2004cited by this paper
• Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors

  2004cited by this paper
• Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances

  2004cited by this paper
• Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates

  2004cited by this paper
• Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.

  2003cited by this paper
• Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

  2003cited by this paper
• The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine

  2003cited by this paper
• Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.

  2003cited by this paper
• Contribution of Individual Cytochrome P450 Isozymes to theO-Demethylation of the Psychotropic β-Carboline Alkaloids Harmaline and Harmine

  2003cited by this paper
• 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens.

  2002cited by this paper
• Experimental toxicity of Peganum harmala seeds.

  2002cited by this paper
• Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method.

  2001cited by this paper
• Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine

  2001cited by this paper
• Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS.

  2001cited by this paper
• The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.

  2001cited by this paper
• Pharmañopo—Psychonautics: Human Intranasal, Sublingual, Intrarectal, Pulmonary and Oral Pharmacology of Bufotenine

  2001cited by this paper
• Pharmacogenetics of schizophrenia.

  2000cited by this paper
• Selective breeding of 5-HT(1A) receptor-mediated responses: application to emotion and receptor action.

  2000cited by this paper
• Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors.

  2000cited by this paper
• Bufotenine: Toward an Understanding of Possible Psychoactive Mechanisms

  2000cited by this paper
• The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.

  2000cited by this paper
• Pharmahuasca: human pharmacology of oral DMT plus harmine.

  1999cited by this paper
• Serotonergic receptor subtypes and hallucinogen-induced stimulus control.

  1999cited by this paper
• SEROTONERGIC RECEPTOR SUBTYPES AND HALLUCINOGEN-INDUCED STIMULUS CONTROL

  1998cited by this paper
• Inhibition of monoamine oxidase A by beta-carboline derivatives.

  1997cited by this paper
• Suppressive effect of mitragynine on the 5-methoxy-N,N-dimethyltryptamine-induced head-twitch response in mice.

  1997cited by this paper
• High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model.

  1997cited by this paper
• Inhibition of Monoamine Oxidase A by β-Carboline Derivatives

  1997cited by this paper
• Gangliosides attenuate stress-induced changes on body weight, motor activity and on the behavioral response to 5-methoxy-N,N-dimethyltryptamine.

  1996cited by this paper
• Assessment of relative efficacies of 5-HT1A receptor ligands by means of in vivo animal models.

  1996cited by this paper
• Tissue distribution, metabolism and effects of bufotenine administered to rats.

  1995cited by this paper
• Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism.

  1995cited by this paper
• Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders.

  1995cited by this paper
• Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines.

  1994cited by this paper
• Bufo alvarius: a potent hallucinogen of animal origin.

  1994cited by this paper
• 5-HT1A and 5-HT2 receptors mediate discrete behaviors in the Mongolian gerbil.

  1992cited by this paper
• 5-Methoxytryptamine is metabolized by monoamine oxidase A in the pineal gland and plasma of golden hamsters.

  1991cited by this paper
• Do classical hallucinogens act as 5-HT2 agonists or antagonists?

  1990cited by this paper
• Do functional relationships exist between 5-HT1A and 5-HT2 receptors?

  1990cited by this paper
• Observations on the metabolism of the psychotomimetic indolealkylamines: implications for future clinical studies.

  1990cited by this paper
• Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis

  1989cited by this paper
• In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat.

  1987cited by this paper
• Urinary excretion of 5-methoxy-N,N-dimethyltryptamine, N,N-dimethyltryptamine and their N-oxides in the rat.

  1987cited by this paper
• Study of metabolism of psychotomimetic indolealkylamines by rat tissue extracts using liquid chromatography.

  1987cited by this paper
• Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors.

  1986cited by this paper
• Bufotenine reconsidered

  1985cited by this paper
• Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat.

  1985cited by this paper
• Biochemistry and Pharmacology of Tryptamines and β-Carbolines A Minireview

  1984cited by this paper
• Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.

  1984cited by this paper
• Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview.

  1984cited by this paper
• The ion-pair extraction, purification, and liquid chromatographic analysis of indolealkylamines in human urine.

  1983cited by this paper
• Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase.

  1981cited by this paper
• Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy.

  1981cited by this paper
• Psilocin, bufotenine and serotonin: historical and biosynthetic observations.

  1979cited by this paper
• Identification of dimethyltryptamine and O-methylbufotenin in human cerebrospinal fluid by combined gas chromatography/mass spectrometry.

  1979cited by this paper

• Vigilance state dissociation induced by 5-MeO-DMT in mice

  2026cites this paper
• A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression.

  2026cites this paper
• Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind

  2026cites this paper
• Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data

  2026cites this paper
• Mapping ligands for MT1/MT2 and 5-HT2C receptors: Chemotypes, SAR, and polypharmacology.

  2026cites this paper
• We Licked the Toads so You Don’t Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5‐Methoxy‐N,N‐Dimethyltryptamine

  2026cites this paper
• Structural Pharmacology of Bufotenine Derivatives in Activating the 5-HT1A Receptor for Therapeutic Potential in Depression and Anxiety

  2025cites this paper
• Hemp Proteins Conjugated with Green Tea Polyphenol Extract Form De Novo Plant‐Sourced Emulsifiers Suitable for Nanodelivery Systems Bearing Lipophilic Psychopharmaceuticals

  2025cites this paper
• The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry

  2025cites this paper
• Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics.

  2025cites this paper
• Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

  2025cites this paper
• The Invasive Mechanism and Impact of Arundo donax, One of the World’s 100 Worst Invasive Alien Species

  2025cites this paper
• A Toad Less Traveled: Should 5-MeO-DMT Have a Role in Treating Depression?

  2025cites this paper
• Beyond Snakes: Exploring Zootoxins in Invertebrates and Lower Vertebrates

  2025cites this paper
• Cardiac effects of two hallucinogenic natural products, N,N-dimethyl-tryptamine and 5-methoxy-N,N-dimethyl-tryptamine

  2025cites this paper
• A Review on the Potential Health Concerns of New Psychoactive Substances on Pregnancy and Lactation: An Overlooked Threat

  2025cites this paper
• Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression.

  2025cites this paper
• Clinical pharmacology.

  2025cites this paper
• Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria and their implications for hospital practice.

  2025cites this paper
• 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.

  2025cites this paper
• Neurotropic Effects In Vivo of New Tryptamino-Triazines Compared to GABA Effectors.

  2025cites this paper
• Transcriptomics and Proteomics Identify Serotonin Transporter as a Promising Therapeutic Target for Essential Tremor

  2025cites this paper
• Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.

  2024cites this paper
• Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice.

  2024cites this paper
• Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy

  2024influential citation
• Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials

  2024cites this paper
• Novel Thermosensitive and Mucoadhesive Nasal Hydrogel Containing 5-MeO-DMT Optimized Using Box-Behnken Experimental Design

  2024cites this paper
• Toxicology and Pharmacological Interactions of Classic Psychedelics.

  2024cites this paper
• Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice

  2024cites this paper
• Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance

  2024cites this paper
• Characterization of Tridax procumbens amines with a potential to synthesize silver nanoparticles

  2024cites this paper
• Multi-omics Identify Serotonin Transporter as a Promising Therapeutic Target for Essential Tremor

  2024cites this paper
• Metabolite markers for three synthetic tryptamines N‐ethyl‐N‐propyltryptamine, 4‐hydroxy‐N‐ethyl‐N‐propyltryptamine, and 5‐methoxy‐N‐ethyl‐N‐propyltryptamine

  2024cites this paper
• Effects of hallucinogenic drugs on the human heart

  2024cites this paper
• Making Sense Of Psychedelics In The CNS.

  2024cites this paper
• 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice

  2023cites this paper
• Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.

  2023cites this paper
• 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

  2023cites this paper
• Bioproduction platform using a novel cane toad (Rhinella marina) N-methyltransferase for psychedelic-inspired drug discovery

  2023cites this paper
• Evaluation of therapeutic role of harmaline: in vitro cytotoxicity targeting nucleic acids

  2023cites this paper
• The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits

  2023influential citation
• Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.

  2023cites this paper
• Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”

  2023influential citation
• "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".

  2023cites this paper
• Incilius alvarius Cell-Based Synthesis of 5-Methoxy-N,N-Dimethyltryptamine

  2023cites this paper
• Cardiovascular effects of bufotenin on human 5-HT4 serotonin receptors in cardiac preparations of transgenic mice and in human atrial preparations

  2023cites this paper
• Transcriptomic Analysis of Glycosylation and Neuroregulatory Pathways in Rodent Models in Response to Psychedelic Molecules

  2023cites this paper
• 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.

  2023cites this paper
• Toad in the road: Biocultural history and conservation challenges of the Sonoran Desert Toad

  2023cites this paper
• 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

  2023cites this paper
• Ayahuasca as a Decoction Applied to Human: Analytical Methods, Pharmacology and Potential Toxic Effects

  2022cites this paper
• The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)

  2022cites this paper
• Pharmahuasca and DMT Rescue ROS Production and Differentially Expressed Genes Observed after Predator and Psychosocial Stress: Relevance to Human PTSD.

  2022cites this paper
• 8th Edition

  2022cites this paper
• 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice

  2022cites this paper
• Key Characteristics and Development of Psychoceuticals: A Review

  2022cites this paper
• Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence

  2022cites this paper
• 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs

  2022cites this paper
• Chemical Characterization and Molecular Dynamics Simulations of Bufotenine by Surface-Enhanced Raman Scattering (SERS) and Density Functional Theory (DFT)

  2022cites this paper
• Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions

  2022cites this paper
• Incilius alvarius cell-based synthesis of 5-MeO-DMT

  2022cites this paper
• Psychedelics and Anti-inflammatory Activity in Animal Models.

  2022cites this paper
• Tryptamines

  2022cites this paper
• In silico study of dimethyltryptamine analogues against 5-HT1B receptor: Molecular docking, dynamic simulations and ADMET prediction

  2022cites this paper
• Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

  2022cites this paper
• Intoxication by 3-MeO-PCP and O-desmethyltramadol: an unusual NPS mix

  2022cites this paper
• Revisiting Forbidden Drugs: Chemical and Pharmacological Perspectives Over Psychedelic Indoleamines and Entactogens as Promising Therapeutic Agents

  2022cites this paper
• 5‐MeO‐DMT has not been found in traditional ayahuasca preparations and the combination of 5‐MeO‐DMT with MAOIs is dangerous

  2022cites this paper
• Serotonin toxicity of serotonergic psychedelics

  2021cites this paper
• Changing Pattern of Chemsex Drug Use Among Newly Diagnosed HIV-Positive Taiwanese from 2015 to 2020 in the Era of Treat-All Policy

  2021cites this paper
• Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

  2021cites this paper
• 5-Methoxy-N,N-di-n-propyltryptamine (5-MeO-DPT): freebase and fumarate

  2021cites this paper
• Fatal intoxication related to two new arylcyclohexylamine derivatives (2F-DCK and 3-MeO-PCE).

  2021cites this paper
• Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism

  2021cites this paper
• Case Report: Synucleinopathy Associated With Phalaris Neurotoxicity in Sheep

  2021cites this paper
• Pharmacology and Neurotoxicity of 5-MeO-DIPT

  2021cites this paper
• Toxicity of psychedelic drugs

  2021cites this paper
• A narrative synthesis of research with 5-MeO-DMT

  2021cites this paper
• An Overview of Alkaloids Derived from Tryptophan and Their Potential Antidepressant Action

  2021cites this paper
• A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

  2021cites this paper
• Toxicology and Analysis of Psychoactive Tryptamines

  2020cites this paper
• Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

  2020cites this paper
• Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore.

  2020cites this paper
• Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use

  2020cites this paper
• N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo

  2020cites this paper
• The pharmacological interaction of compounds in ayahuasca: a systematic review

  2020cites this paper
• A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting

  2020cites this paper
• Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects

  2020cites this paper
• Quantum chemical (QM:MM) investigation of the mechanism of enzymatic reaction of tryptamine and N,N-dimethyltryptamine with monoamine oxidase A.

  2020cites this paper
• Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo

  2019cites this paper
• The morphological and functional characteristics of the pineal gland

  2019cites this paper
• Plant poisoning leads to alpha-synucleinopathy and neuromelanopathy in kangaroos

  2019cites this paper
• 5-methoxy-N,N-dimethyltryptamine: An ego-dissolving endogenous neurochemical catalyst of creativity

  2019cites this paper
• Transformative Psychopharmacology: the Case of 5-Methoxy-N,N-Dimethyltryptamine

  2019cites this paper
• Tridax Procumbens Amines Have A Potential To Synthesize Silver Nanoparticles

  2019cites this paper
• A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms

  2019cites this paper
• Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment

  2019cites this paper
• Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

  2018cites this paper
• A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.

  2018cites this paper
• β-Carboline alkaloid monomers and dimers: Occurrence, structural diversity, and biological activities.

  2018cites this paper